Raise closed, search for fresh raises on Seedstage

Wesley Chapel, FL

Expanding AI-powered continuous monitoring solutions to improve chronic disease management.

• Proprietary technology: Patent-pending BIO-Eye™ Clinical Analytics Platform for real-time patient monitoring.
• Experienced leadership: Team with proven success in national tele-stroke care models.
• Proven impact: Clinical study demonstrated a significant reduction in hospital readmissions.
• Market opportunity: Targeting a $12 billion segment of the chronic disease market.
• Strategic expansion: Active partnerships and deployments across multiple states.

ONEai Health is raising funds to expand the reach of its AI-powered platform designed to transform chronic disease management. The company’s proprietary BIO-Eye™ Clinical Analytics Platform continuously monitors patient biometrics, providing predictive insights to clinicians for early intervention and proactive care. By addressing the high rate of hospital readmissions among chronic disease patients, ONEai Health aims to improve patient outcomes, lower healthcare costs, and support providers with smarter clinical surveillance. The offering supports ONEai Health’s plans to enhance its technology, expand into new markets, and fuel growth initiatives already underway across multiple states.

With a leadership team experienced in healthcare innovation and a track record of success in building telehealth models, ONEai Health focuses on providing solutions for shared-risk organizations and healthcare professionals managing chronic conditions. Their technology delivers actionable analytics from continuous biometric monitoring, helping detect problems before they escalate. The funds from this offering are intended to accelerate strategic partnerships, advance AI development, and broaden customer adoption within a $12 billion target market segment. ONEai Health is committed to building a future where chronic disease management is proactive, efficient, and patient-centered.

Company Info

ONEai Health uses AI to monitor chronic conditions continuously, reducing readmissions and healthcare costs.

ONEai Health is transforming chronic disease management with its AI-driven BIO-Eye™ platform, delivering continuous clinical surveillance to reduce hospital readmissions and improve patient outcomes. Patients wear smart devices that capture biometric data 24/7, enabling real-time predictive insights for proactive intervention. A three-month internal study showed a 71% reduction in hospital readmissions among post-stroke patients using ONEai’s platform.

With traction across 11 states, $1.6M signed ARR, six patent-pending AI algorithms, and leadership that revolutionized Tele-Stroke care nationally, ONEai Health targets a $12B opportunity in the $59B readmission sector of the $4T chronic care market.